title: Benefits on coronary restenosis from elective paclitaxel-eluting stent implantation in patients aged 75 years and older.
abstract: OBJECTIVE
  Elderly patients are increasingly referred for revascularisation yet have been underrepresented in some large clinical trials. Although the advent of drug-eluting stents has dramatically reduced clinical events related to restenosis, older age remains one of the most important correlates of adverse outcome, even after an elective percutaneous coronary intervention (PCI). We sought to evaluate the impact of paclitaxel-eluting stents on coronary restenosis in elderly patients undergoing elective PCI.
  
  
  METHODS
  Patients undergoing successful elective PCI with stenting of de novo coronary artery lesions were identified and screened for participation in this study. All patients included in our analysis were divided into two cohort groups: patients aged <75 years (younger cohort) and patients aged >or=75 years (elderly cohort). We evaluated the six-month incidence of target lesion revascularisation (TLR) and major adverse cardiac events, which included TLR, death and myocardial infarction.
  
  
  RESULTS
  A total of 171 (58 aged >or=75 years) consecutive patients were enrolled in the study. At six months, TLR rate was similar in both groups [1.77 vs. 1.72%, odds ratio (OR) 0.97, 95% confidence interval (CI) 0.08-10.9, P = 0.98, in the younger and elderly group, respectively]. Even the rate of major adverse cardiac events was comparable between the two groups (7.96 vs. 8.62%, OR 1.09, 95% CI 0.34-3.41, P = 0.88, in the younger and elderly group, respectively). Also the angiographic restenosis rates were comparable between patients <75 or >or=75 years (4.42 vs. 3.46%, P = 0.76).
  
  
  CONCLUSIONS
  After elective paclitaxel-eluting stent implantation, there is no difference in coronary restenosis in younger and elderly patients, suggesting an age-independent efficacy.
authors.affiliation: Department of Cardiovascular and Respiratory Sciences, La Sapienza University, Rome, Italy. rino.sardella@uniromal.it
authors.forename: Gennaro
authors.initials: G
authors.lastname: Sardella
authors.forename: Leonardo
authors.initials: L
authors.lastname: De Luca
authors.forename: Giovanni
authors.initials: G
authors.lastname: De Persio
authors.forename: Riccardo
authors.initials: R
authors.lastname: Colantonio
authors.forename: Alessandro
authors.initials: A
authors.lastname: Petrolini
authors.forename: Giulia
authors.initials: G
authors.lastname: Conti
authors.forename: Francesco
authors.initials: F
authors.lastname: Fedele
mesh_terms: D000368:Aged; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009204:Myocardial Revascularization / Q000706:statistics & numerical data; D017239:Paclitaxel / Q000627:therapeutic use*; D015607:Stents; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D017239:Paclitaxel